BioCardia, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
BioCardia, Inc. (BCDA) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $22.35 per share for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-26.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2025-03-26
- BioCardia, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2023-03-31 was $1.49.
- BioCardia, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2021-03-31 was $2.49.
- BioCardia, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2018-03-31 was $1.80, a 800.00% increase year-over-year.
- BioCardia, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2017-03-31 was $0.20.
- BioCardia, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $22.35.
- BioCardia, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- BioCardia, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2021 was $2.49.
- BioCardia, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2018 was $1.80, a 3.74% decline from fiscal 2017.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2023-12-31 | $22.35 10-K · filed 2025-03-26 | $1.49 10-K · filed 2024-03-27 | |||
| 2023-09-30 | $1.49 10-Q · filed 2023-11-08 | ||||
| 2023-06-30 | $1.49 10-Q · filed 2023-08-09 | ||||
| 2023-03-31 | $1.49 10-Q · filed 2023-05-10 | ||||
| 2022-12-31 | $0.00 10-K · filed 2023-03-29 | ||||
| 2021-12-31 | $2.49 10-K · filed 2022-03-29 | ||||
| 2021-09-30 | $2.49 10-Q · filed 2021-11-10 | ||||
| 2021-06-30 | $2.49 10-Q · filed 2021-08-12 | ||||
| 2021-03-31 | $2.49 10-Q · filed 2021-05-13 | ||||
| 2018-12-31 | $1.80 10-K · filed 2019-04-02 | ||||
| 2018-09-30 | $1.80 10-Q · filed 2018-11-08 | ||||
| 2018-06-30 | $1.80 10-Q · filed 2018-08-09 | ||||
| 2018-03-31 | $1.80 10-Q · filed 2018-05-10 | ||||
| 2017-12-31 | $1.87 10-K · filed 2018-03-16 | ||||
| 2017-09-30 | $2.08 10-Q · filed 2017-11-09 | ||||
| 2017-06-30 | $0.20 10-Q · filed 2017-08-14 | ||||
| 2017-03-31 | $0.20 10-Q · filed 2017-05-11 | ||||
| 2016-12-31 | $0.14 10-K · filed 2017-03-30 | ||||
| 2016-09-30 | $0.00 10-Q · filed 2016-10-17 | ||||
| 2016-06-30 | $0.00 10-Q · filed 2016-08-02 | ||||
| 2016-03-31 | $0.00 10-Q · filed 2016-05-03 | ||||
| 2015-12-31 | $0.00 10-K · filed 2016-03-25 | ||||
| 2015-09-30 | $0.00 10-Q · filed 2015-10-29 | ||||
| 2015-06-30 | $0.00 10-Q · filed 2015-08-12 | ||||
| 2015-03-31 | $0.00 10-Q · filed 2015-05-12 | ||||
| 2014-12-31 | $0.00 10-K · filed 2015-03-24 | ||||
| 2014-09-30 | $0.00 10-Q · filed 2014-11-06 | ||||
| 2014-06-30 | $0.00 10-Q · filed 2014-08-06 | ||||
| 2014-03-31 | $0.00 10-Q · filed 2014-05-12 | ||||
| 2013-12-31 | $0.00 10-K · filed 2014-03-24 | ||||
| 2013-09-30 | $0.00 10-Q · filed 2013-11-01 | ||||
| 2013-06-30 | $0.00 10-Q · filed 2013-07-26 | ||||
| 2012-12-31 | $0.00 10-K · filed 2014-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |